Tags

Type your tag names separated by a space and hit enter

Prognostic factors in lymph node-positive prostate cancer.
Urology. 2006 May; 67(5):1016-21.U

Abstract

OBJECTIVES

To characterize lymph node metastasis of prostate cancer (PCa) and identify the parameters associated with patient outcome. The incidence of clinically localized PCa with concurrent lymph node metastasis has decreased to less than 1% in the United States but is between 10% and 15% in other countries.

METHODS

Our study cohort of 1148 patients underwent radical prostatectomy in Ulm, Germany, between 1986 and 2002, and 201 (18%) had lymph node-positive PCa.

RESULTS

The metastases showed growth architecture resembling primary PCa. We assigned a Gleason pattern and evaluated for size, extranodal extension, and lymphovascular invasion (LVI). Of 201 patients, 155 had original pathology slides available; 36 of the 155 were excluded because of preoperative hormonal ablation therapy. Of the remaining 119 patients, 22 (19%) were assigned Gleason pattern 3, 93 (78%) Gleason pattern 4, and 4 (3%) Gleason pattern 5. Extranodal extension was present in 66 (55%) of 119 patients and LVI in 29 (25%). An increased risk of prostate-specific antigen (PSA) recurrence was found for Gleason pattern 4/5 (hazard ratio [HR] 2.5, P = 0.038), LVI in the lymph nodes (HR 1.9, P = 0.038), and nuclear grade of the primary tumor (HR 2, P = 0.025). Independent predictors of PSA recurrence included LVI and nuclear grade (HR 1.9, P = 0.03 and HR 2, P = 0.03, respectively).

CONCLUSIONS

Lymph node metastases of PCa are heterogeneous and have a close relation to the corresponding primary tumor. Most patients with lymph node-positive PCa remained disease free for up to 13 years after radical prostatectomy. Independent predictors of PSA recurrence among those with lymph node-positive PCa included LVI in the lymph nodes and the nuclear grade of the primary tumor. These parameters may be useful in predicting PSA recurrence in lymph node-positive PCa and could be included in patient follow-up.

Authors+Show Affiliations

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

16698361

Citation

Hofer, Matthias D., et al. "Prognostic Factors in Lymph Node-positive Prostate Cancer." Urology, vol. 67, no. 5, 2006, pp. 1016-21.
Hofer MD, Kuefer R, Huang W, et al. Prognostic factors in lymph node-positive prostate cancer. Urology. 2006;67(5):1016-21.
Hofer, M. D., Kuefer, R., Huang, W., Li, H., Bismar, T. A., Perner, S., Hautmann, R. E., Sanda, M. G., Gschwend, J. E., & Rubin, M. A. (2006). Prognostic factors in lymph node-positive prostate cancer. Urology, 67(5), 1016-21.
Hofer MD, et al. Prognostic Factors in Lymph Node-positive Prostate Cancer. Urology. 2006;67(5):1016-21. PubMed PMID: 16698361.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic factors in lymph node-positive prostate cancer. AU - Hofer,Matthias D, AU - Kuefer,Rainer, AU - Huang,Wei, AU - Li,Haojie, AU - Bismar,Tarek A, AU - Perner,Sven, AU - Hautmann,Richard E, AU - Sanda,Martin G, AU - Gschwend,Juergen E, AU - Rubin,Mark A, PY - 2005/08/20/received PY - 2005/10/03/revised PY - 2005/10/31/accepted PY - 2006/5/16/pubmed PY - 2006/5/26/medline PY - 2006/5/16/entrez SP - 1016 EP - 21 JF - Urology JO - Urology VL - 67 IS - 5 N2 - OBJECTIVES: To characterize lymph node metastasis of prostate cancer (PCa) and identify the parameters associated with patient outcome. The incidence of clinically localized PCa with concurrent lymph node metastasis has decreased to less than 1% in the United States but is between 10% and 15% in other countries. METHODS: Our study cohort of 1148 patients underwent radical prostatectomy in Ulm, Germany, between 1986 and 2002, and 201 (18%) had lymph node-positive PCa. RESULTS: The metastases showed growth architecture resembling primary PCa. We assigned a Gleason pattern and evaluated for size, extranodal extension, and lymphovascular invasion (LVI). Of 201 patients, 155 had original pathology slides available; 36 of the 155 were excluded because of preoperative hormonal ablation therapy. Of the remaining 119 patients, 22 (19%) were assigned Gleason pattern 3, 93 (78%) Gleason pattern 4, and 4 (3%) Gleason pattern 5. Extranodal extension was present in 66 (55%) of 119 patients and LVI in 29 (25%). An increased risk of prostate-specific antigen (PSA) recurrence was found for Gleason pattern 4/5 (hazard ratio [HR] 2.5, P = 0.038), LVI in the lymph nodes (HR 1.9, P = 0.038), and nuclear grade of the primary tumor (HR 2, P = 0.025). Independent predictors of PSA recurrence included LVI and nuclear grade (HR 1.9, P = 0.03 and HR 2, P = 0.03, respectively). CONCLUSIONS: Lymph node metastases of PCa are heterogeneous and have a close relation to the corresponding primary tumor. Most patients with lymph node-positive PCa remained disease free for up to 13 years after radical prostatectomy. Independent predictors of PSA recurrence among those with lymph node-positive PCa included LVI in the lymph nodes and the nuclear grade of the primary tumor. These parameters may be useful in predicting PSA recurrence in lymph node-positive PCa and could be included in patient follow-up. SN - 1527-9995 UR - https://www.unboundmedicine.com/medline/citation/16698361/Prognostic_factors_in_lymph_node_positive_prostate_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-4295(05)01609-2 DB - PRIME DP - Unbound Medicine ER -